Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

CYB005

From Wikipedia, the free encyclopedia
Serotonergic psychedelic
Pharmaceutical compound
CYB005
Clinical data
Other namesCYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative
Drug classSerotonin receptor agonist;Serotonergic psychedelic;Antiinflammatory drug[1]

CYB005, orCYB-005, also known asdeuterated phenethylamine derivative, is aserotonin receptor agonist andserotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment ofpsychiatric disorders andneuroinflammation.[2][3][1]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

CYB005 acts as aserotonin receptoragonist and is aserotonergic psychedelic.[2][1] In addition, CYB005 may alsoinhibitserotonin anddopaminereuptake.[1]

Chemistry

[edit]

It is aphenethylaminederivative and adeuteratedcompound.[2][3][1] The exactchemical structure of CYB005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related toCYB210010, which itself is non-deuterated.[4][5][6] In addition, CYB005's developer haspatent protection for the compound, indicating that its chemical structure has been published in thepatent literature.[2][4][7]

Development

[edit]

As of October 2024, CYB005 is in theresearch or preclinical stage of development.[2][3] It has been in this developmental stage since at least 2022.[1] The drug is under development byCybin.[2][3][1] Other related drugs include the deuteratedtryptaminesCYB003 andCYB004.[1][8]

See also

[edit]

References

[edit]
  1. ^abcdefghiCano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B (December 2022)."Key Characteristics and Development of Psychoceuticals: A Review".Int J Mol Sci.23 (24) 15777.doi:10.3390/ijms232415777.PMC 9779201.PMID 36555419.Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.
  2. ^abcdefg"CYB 005".AdisInsight. 28 October 2024. Retrieved10 November 2024.CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders.
  3. ^abcd"Delving into the Latest Updates on CYB-005 with Synapse".Synapse. 1 November 2024. Retrieved10 November 2024.
  4. ^ab"Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program".Yahoo Finance. 24 October 2024. Retrieved10 November 2024.
  5. ^Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist".J Med Chem.67 (8):6144–6188.doi:10.1021/acs.jmedchem.3c01961.PMID 38593423.
  6. ^Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, Morgan M, Mueller T, Reichelt A, Pathare P, Stang E, Nivorozhkin A (December 2023)."ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist".Neuropsychopharmacology.48 (Suppl 1): 211–354 (299–299).doi:10.1038/s41386-023-01756-4.PMC 10729596.PMID 38040810.
  7. ^"Therapeutic phenethylamine compositions and methods of use".Google Patents. 18 August 2021. Retrieved10 November 2024.
  8. ^Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?".Nat Biotechnol.42 (6):827–830.doi:10.1038/s41587-024-02285-1.PMID 38831049.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=CYB005&oldid=1316034959"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp